CMR Surgical

CMR Surgical was founded in 2014 in Cambridge, UK (originally as Cambridge Medical Robotics) to develop a soft-tissue surgical robot that could be used more widely than existing systems. Its Versius Surgical Robotic System is a modular, portable platform built from separate bedside units rather than a single large console, intended to fit into existing operating rooms with minimal reconfiguration.

Versius received CE marking in March 2019 and began clinical use later that year in the UK and India, expanding into other markets including Australia in 2020. In October 2024, Versius became the first multi-port, soft-tissue general-surgery robotic-assisted surgical device authorized by the U.S. FDA through the De Novo pathway, clearing the way for a U.S. commercial launch. As of March 2026 the company said more than 45,000 patients had been treated globally using Versius, and CMR reports it is the second most widely used soft-tissue surgical robotics platform in the world after Intuitive Surgical.

The company remains privately held and has raised more than $1.1 billion in disclosed equity and debt financing since its Series A in 2016, most recently a combined equity-and-debt round of more than $200 million in April 2025 that included a new debt facility from Trinity Capital. In 2026, CMR Surgical was reported to have engaged advisors to explore a potential sale at a valuation of up to $4 billion, alongside continued expansion of its U.S. commercial launch.